LAVAL, QC and CAMBRIDGE, England, July 17, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, ...
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseases Advancement of clinical trial application (CTA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results